Lung Cancers Completed Phase 2 Trials for Gefitinib (DB00317)

Also known as: LUng Cancer / Cancer, Lung / Lung neoplasm malignant / Lung cancer NOS / Cancer of lung / Ca lung

IndicationStatusPhase
DBCOND0072929 (Lung Cancers)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00452244Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)Treatment
NCT00588445Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor GeneTreatment
NCT00411047Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung CancerTreatment
NCT01530334Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous TreatmentTreatment
NCT00193336Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung CancerTreatment
NCT00238251Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain MetastasesTreatment
NCT00217698Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerTreatment
NCT00103051Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung CancerTreatment
NCT00068653Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung CancerTreatment
NCT00062062Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung CancerTreatment
NCT00188617Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLCTreatment